Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month High – Still a Buy?

Rapport Therapeutics, Inc. (NASDAQ:RAPP)’s stock price reached a new 52-week high on Thursday . The company traded as high as $44.38 and last traded at $44.33, with a volume of 39808 shares trading hands. The stock had previously closed at $42.44.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: BTIG Research reiterated its Buy rating, supporting the bullish view that Rapport’s epilepsy pipeline could create significant value. BTIG Research Reiterates Buy Rating for Rapport Therapeutics
• Positive Sentiment: H.C. Wainwright also maintained a Buy rating, citing Rapport’s advancing Phase 3 epilepsy program and a development path it considers increasingly de-risked. However, its $40 price target is below the stock’s recent trading level, limiting the immediate upside implied by the report. Rapport Therapeutics Advancing Phase 3 Epilepsy Pipeline and De-Risked Development Path Underpins Buy Rating
• Neutral Sentiment: H.C. Wainwright’s updated estimates call for losses of $1.36 per share in the third quarter and $1.54 per share in the fourth quarter of 2026. The firm projects a $4.51-per-share loss for full-year 2026, compared with the broader consensus estimate of a $3.67 loss, indicating higher expected near-term cash burn.
• Negative Sentiment: H.C. Wainwright projects continued losses through 2030: $6.80 per share in 2027, $8.40 in 2028, $8.08 in 2029, and $6.96 in 2030. These forecasts reinforce concerns that profitability may remain distant and that the company could require additional financing.
• Negative Sentiment: Wall Street Zen downgraded RAPP to Sell, adding a clearly bearish signal and contributing to pressure on the stock. Rapport Therapeutics Downgraded by Wall Street Zen to Sell

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on RAPP. Leerink Partners initiated coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $52.00 target price on the stock. Wall Street Zen downgraded shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a research report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Friday, July 17th. Finally, Raymond James Financial started coverage on Rapport Therapeutics in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $66.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $57.86.

Rapport Therapeutics Stock Performance

The stock has a 50-day simple moving average of $39.77 and a two-hundred day simple moving average of $34.55. The firm has a market cap of $2.18 billion, a PE ratio of -14.96 and a beta of 0.97.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, sell-side analysts anticipate that Rapport Therapeutics, Inc. will post -3.67 EPS for the current fiscal year.

Insider Buying and Selling

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 2,210 shares of Rapport Therapeutics stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $42.11, for a total value of $93,063.10. Following the completion of the sale, the chief executive officer owned 537,607 shares of the company’s stock, valued at approximately $22,638,630.77. The trade was a 0.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Rock Ventures V. L.P. Third sold 133,618 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $40.24, for a total transaction of $5,376,788.32. Following the sale, the insider owned 6,299,097 shares of the company’s stock, valued at approximately $253,475,663.28. This represents a 2.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 154,400 shares of company stock worth $6,213,660. 12.48% of the stock is owned by insiders.

Hedge Funds Weigh In On Rapport Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of RAPP. Swedbank AB bought a new position in shares of Rapport Therapeutics in the 4th quarter worth approximately $3,434,000. Goldman Sachs Group Inc. lifted its position in Rapport Therapeutics by 23.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 3,001,879 shares of the company’s stock valued at $91,077,000 after purchasing an additional 579,903 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Rapport Therapeutics by 11.8% during the 4th quarter. Vanguard Group Inc. now owns 1,817,757 shares of the company’s stock valued at $55,151,000 after buying an additional 191,219 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Rapport Therapeutics during the first quarter valued at approximately $1,121,000. Finally, Artia Global Partners LP boosted its holdings in Rapport Therapeutics by 114.4% in the 4th quarter. Artia Global Partners LP now owns 138,508 shares of the company’s stock worth $4,202,000 after buying an additional 73,900 shares during the period.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.